Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 1092977-61-1
2. 2-((3-butoxyphenethyl)amino)-n,n-dimethylacetamide
3. Evenamide [inn]
4. Nw-3509
5. On5s6n53js
6. Mfcd28502433
7. 2-((2-(3-butoxyphenyl)ethyl)amino)-n,n-dimethylacetamide
8. Acetamide, 2-((2-(3-butoxyphenyl)ethyl)amino)-n,n-dimethyl-
9. 2-[(3-butoxyphenethyl)amino]-n,n-dimethylacetamide
10. Unii-on5s6n53js
11. Evenamid
12. Evenamide [who-dd]
13. Schembl3025285
14. Chembl3678076
15. Bdbm161090
16. Dtxsid101032897
17. Sb18910
18. Ac-35786
19. As-48527
20. Hy-17612
21. Sy244487
22. Cs-0014697
23. F50592
24. Q21098995
25. 2-[2-(3-butoxyphenyl)ethylamino]-n,n-dimethylacetamide
26. Us9051240, 2-[2-(3-butoxyphenyl)-ethylamino]-n,n-dimethylacetamide
| Molecular Weight | 278.39 g/mol |
|---|---|
| Molecular Formula | C16H26N2O2 |
| XLogP3 | 2.5 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 9 |
| Exact Mass | 278.199428076 g/mol |
| Monoisotopic Mass | 278.199428076 g/mol |
| Topological Polar Surface Area | 41.6 Ų |
| Heavy Atom Count | 20 |
| Formal Charge | 0 |
| Complexity | 269 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
Details:
The financing for Evenamide, a miscellaneous product targeting voltage-gated sodium channels, will support the development of treatment-resistant schizophrenia therapies.
Lead Product(s): Evenamide,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: $45.0 million Upfront Cash: Undisclosed
Deal Type: Financing February 16, 2026
Lead Product(s) : Evenamide,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : $45.0 million
Deal Type : Financing
Newron Secures EUR 38M for Phase 3 Evenamide
Details : The financing for Evenamide, a miscellaneous product targeting voltage-gated sodium channels, will support the development of treatment-resistant schizophrenia therapies.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
February 16, 2026
Details:
Evenamide is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Schizophrenia, Treatment-Resistant.
Lead Product(s): Evenamide,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 22, 2025
Lead Product(s) : Evenamide,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Evenamide is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Schizophrenia, Treatment-Resistant.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 22, 2025
Details:
NW-3509 (evenamide), a first-in-class glutamate modulator, which has the potential to be the first add-on therapy for treatment-resistant schizophrenia and for patients with schizophrenia.
Lead Product(s): Evenamide,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 12, 2025
Lead Product(s) : Evenamide,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Newron Wins OK for Phase 3 ENIGMA-TRS Trial with Evenamide in TRS Patients
Details : NW-3509 (evenamide), a first-in-class glutamate modulator, which has the potential to be the first add-on therapy for treatment-resistant schizophrenia and for patients with schizophrenia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 12, 2025
Details:
Under the licensing agreement, Myung will develop, manufacture, and commercialize Newron’s NW-3509 (evenamide) for patients with schizophrenia in South Korea.
Lead Product(s): Evenamide,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Myung In Pharm
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 09, 2025
Lead Product(s) : Evenamide,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Myung In Pharm
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Newron and Myung in Pharm Announce License Agreement for Evenamide in South Korea
Details : Under the licensing agreement, Myung will develop, manufacture, and commercialize Newron’s NW-3509 (evenamide) for patients with schizophrenia in South Korea.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
January 09, 2025
Details:
Under the terms of the license agreement, EA will develop and commercialize Newron’s innovative NW-3509 (evenamide) for treatment-resistant schizophrenia.
Lead Product(s): Evenamide,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: EA Pharma
Deal Size: $122.7 million Upfront Cash: $46.0 million
Deal Type: Licensing Agreement December 13, 2024
Lead Product(s) : Evenamide,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : EA Pharma
Deal Size : $122.7 million
Deal Type : Licensing Agreement
Newron and EA Pharma Sign License for Evenamide in Japan and Asian Regions
Details : Under the terms of the license agreement, EA will develop and commercialize Newron’s innovative NW-3509 (evenamide) for treatment-resistant schizophrenia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : $46.0 million
December 13, 2024
Details:
NW-3509 (evenamide), an orally new chemical entity, specifically blocks voltage-gated sodium channels (VGSCs), is being developed for the treatment of patients with chronic schizophrenia.
Lead Product(s): Evenamide,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 13, 2024
Lead Product(s) : Evenamide,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Newron Reports Efficacy Data from Evenamide Study in Poorly Responding Schizophrenia
Details : NW-3509 (evenamide), an orally new chemical entity, specifically blocks voltage-gated sodium channels (VGSCs), is being developed for the treatment of patients with chronic schizophrenia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 13, 2024
Details:
NW-3509 (evenamide), an orally available new chemical entity, specifically blocks voltage-gated sodium channels (VGSCs), is being developed for the treatment of patients with chronic schizophrenia.
Lead Product(s): Evenamide,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 30, 2024
Lead Product(s) : Evenamide,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Newron Announces Positive Results From Pivotal Phase 2/3 With Evenamide In Schizophrenia
Details : NW-3509 (evenamide), an orally available new chemical entity, specifically blocks voltage-gated sodium channels (VGSCs), is being developed for the treatment of patients with chronic schizophrenia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 30, 2024
Details:
NW3509 (evenamide) is an oral medication in phase 2 for treatment-resistant schizophrenia, specifically blocking sodium channels with minimal off-target effects.
Lead Product(s): Evenamide,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 04, 2024
Lead Product(s) : Evenamide,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Newron Reports One-Year Results for Evenamide in Treatment-Resistant Schizophrenia
Details : NW3509 (evenamide) is an oral medication in phase 2 for treatment-resistant schizophrenia, specifically blocking sodium channels with minimal off-target effects.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 04, 2024
Details:
NW3509 (evenamide) is an orally available new chemical entity, specifically blocks voltage-gated sodium channels (VGSCs) and is devoid of biological activity at >130 other CNS targets. It is under phase 2 clinical development for the treatment of Schizophrenia.
Lead Product(s): Evenamide,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 29, 2023
Lead Product(s) : Evenamide,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : NW3509 (evenamide) is an orally available new chemical entity, specifically blocks voltage-gated sodium channels (VGSCs) and is devoid of biological activity at >130 other CNS targets. It is under phase 2 clinical development for the treatment of Schizop...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 29, 2023
Details:
NW-3509 (evenamide) is an orally available new chemical entity, specifically blocks voltage-gated sodium channels. It normalizes glutamate release induced by aberrant sodium channel activity (veratridine-stimulated), without affecting basal glutamate levels.
Lead Product(s): Evenamide,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 20, 2023
Lead Product(s) : Evenamide,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : NW-3509 (evenamide) is an orally available new chemical entity, specifically blocks voltage-gated sodium channels. It normalizes glutamate release induced by aberrant sodium channel activity (veratridine-stimulated), without affecting basal glutamate lev...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 20, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
64
PharmaCompass offers a list of Evenamide API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Evenamide manufacturer or Evenamide supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Evenamide manufacturer or Evenamide supplier.
PharmaCompass also assists you with knowing the Evenamide API Price utilized in the formulation of products. Evenamide API Price is not always fixed or binding as the Evenamide Price is obtained through a variety of data sources. The Evenamide Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Evenamide manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Evenamide, including repackagers and relabelers. The FDA regulates Evenamide manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Evenamide API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Evenamide supplier is an individual or a company that provides Evenamide active pharmaceutical ingredient (API) or Evenamide finished formulations upon request. The Evenamide suppliers may include Evenamide API manufacturers, exporters, distributors and traders.
Evenamide Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Evenamide GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Evenamide GMP manufacturer or Evenamide GMP API supplier for your needs.
A Evenamide CoA (Certificate of Analysis) is a formal document that attests to Evenamide's compliance with Evenamide specifications and serves as a tool for batch-level quality control.
Evenamide CoA mostly includes findings from lab analyses of a specific batch. For each Evenamide CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Evenamide may be tested according to a variety of international standards, such as European Pharmacopoeia (Evenamide EP), Evenamide JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Evenamide USP).
